Aeglea BioTherapeutics (NASDAQ:AGLE) Price Target Cut to $7.00 by Analysts at Piper Sandler

Aeglea BioTherapeutics (NASDAQ:AGLEGet Rating) had its price objective reduced by Piper Sandler from $9.00 to $7.00 in a report issued on Friday, The Fly reports.

AGLE has been the topic of a number of other reports. StockNews.com began coverage on shares of Aeglea BioTherapeutics in a research report on Thursday, March 31st. They set a hold rating on the stock. Zacks Investment Research raised shares of Aeglea BioTherapeutics from a sell rating to a hold rating in a research note on Wednesday, March 30th. Finally, HC Wainwright lowered their price objective on shares of Aeglea BioTherapeutics from $20.00 to $17.00 in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of Buy and a consensus target price of $12.65.

AGLE traded down $0.19 during midday trading on Friday, hitting $1.39. The company had a trading volume of 219,335 shares, compared to its average volume of 989,646. Aeglea BioTherapeutics has a twelve month low of $1.37 and a twelve month high of $8.50. The firm’s 50-day simple moving average is $2.16 and its 200-day simple moving average is $4.03.

Aeglea BioTherapeutics (NASDAQ:AGLEGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, research analysts predict that Aeglea BioTherapeutics will post -1.43 EPS for the current year.

In related news, CEO Anthony G. Quinn bought 67,472 shares of the company’s stock in a transaction that occurred on Monday, March 14th. The shares were acquired at an average price of $1.93 per share, for a total transaction of $130,220.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Anthony G. Quinn purchased 34,777 shares of the firm’s stock in a transaction on Friday, March 11th. The stock was bought at an average price of $2.06 per share, with a total value of $71,640.62. The disclosure for this purchase can be found here. Insiders have purchased 257,328 shares of company stock valued at $545,246 in the last 90 days. 3.80% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in shares of Aeglea BioTherapeutics by 84.4% in the 3rd quarter. Royal Bank of Canada now owns 5,468 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 2,502 shares during the period. Pinnacle Wealth Planning Services Inc. bought a new position in shares of Aeglea BioTherapeutics during the 4th quarter worth approximately $48,000. Citigroup Inc. increased its holdings in shares of Aeglea BioTherapeutics by 66.7% during the 4th quarter. Citigroup Inc. now owns 11,894 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 4,761 shares during the last quarter. Nisa Investment Advisors LLC acquired a new position in shares of Aeglea BioTherapeutics during the 4th quarter worth approximately $57,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in Aeglea BioTherapeutics by 128.6% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 10,756 shares of the biotechnology company’s stock valued at $86,000 after purchasing an additional 6,051 shares during the last quarter. 84.13% of the stock is owned by institutional investors.

Aeglea BioTherapeutics Company Profile (Get Rating)

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.

See Also

The Fly logo

Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.